Teladoc Health reported a 15% increase in revenue for Q4 2022, reaching $637.7 million. However, the company experienced a net loss of $3,810.1 million, or ($23.49) per share, primarily due to non-cash goodwill impairment charges of $3.8 billion.
Revenue grew 15% year-over-year to $637.7 million.
Net loss per share was ($23.49), driven by non-cash goodwill impairment charges.
Adjusted EBITDA increased 22% to $94.1 million.
U.S. revenues grew 15% and International revenues grew 17%.
Teladoc Health provided financial outlook for Q1 2023 and full year 2023.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance